E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
After 20 weeks, to assess the effect of treatment with MK-0941 compared with placebo on A1C when added to basal insulin.
|
|
E.2.2 | Secondary objectives of the trial |
(1) To assess the safety and tolerability of MK-0941. (2) After 20 weeks, to assess the effect of treatment with MK-0941 compared with placebo on fasting plasma glucose when added to basal insulin. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patient is between 21 and 70 years of age. 2. Patient has type 2 diabetes mellitus and meets one of the following criteria: • On a stable dose of Lantus insulin monotherapy >=15 units/day for at least 6 weeks and has a Visit 1/Screening Visit A1C of ≥7.5% and 11.0% • On any injectable insulin (other than Lantus) at a stable dose of >=15 units/day, either alone or in combination with an oral monotherapy agent for at least 6 weeks and has a Visit 1/Screening A1C of ≥7.0% and 10.5% • On any injectable insulin at a stable dose of >=15 units/day, in combination with two oral agents for at least 6 weeks and has a Visit 1/Screening A1C of ≥6.5% and <=10.0% 3. Patient is a male or a female who is highly unlikely to conceive (i.e., patient is a male, patient is not of reproductive potential, patient is of reproductive potential and agrees to remain abstinent or use 2 acceptable methods of birth control).
|
|
E.4 | Principal exclusion criteria |
1. Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis. 2. Patient has received more than 1 week of dosing of TZD therapy within the past 8 weeks. 3. Patient has a history of severe hypoglycemia defined as 2 or more episodes during his/her lifetime or one episode within the past year that resulted in hypoglycemic seizures and/or cerebral impairment (e.g. coma, severe confusion, etc.) or patient has had hypoglycemia unawareness (i.e.,fingerstick glucose <50 mg/dL [2.8 mmol/L] without symptoms) within the past 3 months. 4. Patient has a contraindication to Lantus insulin. 5. Patient is allergic to ophthalmologic dilation medications (i.e., cyclophenylate, phenylephrine) 6. Patient meets one of the following medication exclusions: • Taking weight loss medication (e.g. orlistat, sibutramine, rimonabant, etc) within 8 weeks of Visit 1/Screening Visit. • Currently taking or likely to require treatment with > 14 consecutive days or repeated courses of pharmacological doses of systemic (oral, injectable/parenteral) or ocular corticosteroids during the study. (NOTE: oral corticosteroids used for physiologic replacement therapy (e.g. in patients with adrenal insufficiency) and inhaled, nasal, and topical (i.e. dermatological) corticosteroids are allowed). • Currently on or likely to require treatment with warfarin or warfarin-like anticoagulants, digoxin, or any other medication with a narrow therapeutic index. • Under treatment with anti-thyroid medication or radioactive iodine for hyperthyroidism. • Currently treated or likely to require treatment with the following glaucoma medications: ecothiophate, pilocarpine, or carbachol 7. Patient meets one of the following medical exclusions: • New or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months • Any of the following in the past 6 months: acute coronary syndrome, cerebral vascular accident, or TIA • NYHA Class II-IV cardiac status or severe peripheral vascular disease • Chronic myopathy or a progressive neurological or neuromuscular disorder • A systolic blood pressure of ≥160mm Hg or diastolic blood pressure of ≥90mm Hg. • Active nephropathy • Active liver disease (other than non-alcoholic hepatic steatosis), active viral hepatitis, cirrhosis, or symptomatic gallbladder disease • HIV positive • Clinically significant hematological disorder • History of malignancy < 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer (NOTE: Melanoma, leukemia, myeloproliferative disorders and renal cell carcinoma of any duration are excluded) • Ocular herpes, uveitis, or iritis within 3 months prior to screening or has a history of recurrent episodes of any of these three conditions. • Poorly controlled hypertension • Any other condition which, in the opinion of the investigator, might pose a risk to the patient or make participation not in the patient's best interest, that might confound the results of the study, or interfere with the patient's participation for the full duration of the study 8. Patient has undergone surgery within 30 days prior to Visit 1/Screening Visit or has planned major surgery. 9. Patient has had coronary artery intervention (e.g. coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the past 6 months 10. Patient has had, or is anticipated to have intraocular surgery within 6 months prior to Visit 1 or during the study or has had laser eye surgery within 3 months prior to screening (LASIK is permitted). 11. Patient has any existing condition which will preclude Lens Opacities Classification System (LOCS) III examination and retinal examination in both eyes. Note: Patients with history of unilateral or bilateral cataract extraction which occurred more than 6 months prior to screening may participate. 12. At randomization (Visit 5/Day 1) patient has a site fasting fingerstick glucose <130 mg/dL (7.2 mmol/L) or >240 mg/dL (13.3 mmol/L). 13. Patient is pregnant or breast-feeding, or expecting to conceive during the duration of the study. 14. Patient is currently participating, or has participated in a study with an investigational compound or device within 3 months of signing informed consent and is not willing to refrain from participating in another study for 3 months after completing this study. 15. Patient is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history of drug abuse or increased alcohol consumption. 16. Patient has poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in A1C at Week 20. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |